Navigation Links
Resisting lung cancer recurrence
Date:2/4/2008

(New York, February 5th) -- What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years" This concept may no longer be a fantasy. In a clinical study published online this week by the Proceedings of the National Academy of Sciences USA, a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots. Patients with resected non-small cell lung cancer (NSCLC) were treated with this investigational agent, also known as an Antigen-Specific Cancer Immunotherapeutic (ASCI), in another clinical study conducted by GlaxoSmithKline. The results showed a reduction in risk of cancer recurrence in these patients, a finding that prompted GlaxoSmithKline to initiate the largest ever clinical trial in lung cancer (MAGRIT study).

According to LICRs Dr. Sacha Gnjatic, the senior author of this LICR-sponsored study, the long immunological memory is exactly what cancer immunologists are hoping to see. Vaccines against infectious diseases induce immunological responses that typically last for years, and ideally we want a cancer vaccine that does the same thing. We previously learned that our vaccine could stimulate an immune response recognizing a protein found in lung cancer cells but we did not know how long the response lasted. We now know that this vaccine induces strong and persistent immunity over several years, which can be further boosted with additional vaccination. Dr. Gnjatic said that the booster shots, given two years after the first cycle of vaccinations, not only reactivated the initial immune response in patients who received the priming vaccination, it also diversified the types of immune cells specific for the cancer protein. Weve not only kept the immune system interested, weve also got it to more broadly recognize the protein that marks the cell as being a cancer cell.

LICR and the Cancer Research Institute, both head-quartered in New York, supported the study under the auspices of the Cancer Vaccine Collaborative, with the clinical component conducted by Dr. Nasser Altorki at New York Presbyterian Hospital / Weill Medical College of Cornell University.

Cancer vaccines have two principal components. One component, the adjuvant, stimulates the immune system in a general way, and the other component, the tumor antigen in this case, the MAGE-A3 antigen directs the immune response specifically against the cancer cell. Last month, another LICR-sponsored clinical trial within the Cancer Vaccine Collaborative showed that a cancer vaccine based on the tumor antigen NY-ESO-1 stimulated an immune response in women with ovarian cancer. The results from that trial were suggestive that a similar boost strategy could be beneficial for long-term immunological memory in that disease also.

A completely unexpected finding from the present study was that the inital formulation and delivery of the tumor antigen to the immune system is critical and suggests that the combination of the antigen with an immunological adjuvant is key. The original, small clinical study, conducted three years ago by the Cancer Vaccine Collaborative, showed that the adjuvant was necessary for activation of the immune system; patients who received antigen alone failed to mount specific immune responses. Surprisingly, these same patients also failed to mount immune responses even when they received the full vaccine adjuvant plus antigen as a booster shot.

This is such a surprising result, says LICRs Dr. Lloyd Old, another author on the study and Director of the Cancer Vaccine Collaborative. In the vaccine field, boosters are given to convert negative or weak reactions to positive ones, and we really thought we would see the same thing. One intriguing possibility is that regulatory mechanisms were activated following the original weak response induced by the vaccine without adjuvant. These findings will certainly have ramifications for the whole field to determine the formulation and delivery of future cancer vaccines.


'/>"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
917-379-0398
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: Perspectives in ... March 3-4, 2017. This Congress is expertly designed to meet the educational needs ... with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of Oncology at ...
(Date:1/13/2017)... ... ... inventor from Pahrump, Nev., used an unsavory medical experience to think of a way to ... urine bag for a half year due to lazy bladder," he said. "Keeping these things ... better way to do this." , He then designed and created a prototype of the ...
(Date:1/13/2017)... , ... January 13, 2017 , ... Friday, January 13 ... of the game room, increasing the size of the location to 90,000 square feet. ... 8-hole mini golf course that takes customers on an educational tour of the historic ...
(Date:1/13/2017)... ... January 13, 2017 , ... As the nation watches this month’s transition ... colleges and schools of education across the country is urging a fundamental reconsideration of ... Principles released today, 175 deans sounded the alarm: “Our children suffer when we deny ...
(Date:1/13/2017)... ... January 13, 2017 , ... One way to obtain a green card is ... can show their work is in the national interest. There are two significant advantages ... be sponsored by an employer; and 2) the submission is made directly to the ...
Breaking Medicine News(10 mins):
(Date:1/12/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing ... this week,s Orlando Dermatology Aesthetic & Clinical (ODAC) Conference, which ... inflammation. The data will be shared in a ... at ODAC, which is being held Jan. 13-16 in ... ...
(Date:1/12/2017)...   TyrNovo , s NT219 drug candidate ... cancer drug resistance and would be ... NT219 is a novel proprietary ... ( IRS1/2 and STAT3) highly involved in ... .   NT219 has demonstrated ...
(Date:1/12/2017)... -- "Global Lung Cancer Vaccine Market & Pipeline ... trends in the global lung cancer vaccine market. ... available in the market. This report analyzes the ... in clinical pipeline and gives comprehensive clinical insight ... the lung cancer vaccines. Currently there are 9 ...
Breaking Medicine Technology: